CD147-knockdown-plus-trastuzumab treatment significantly inhibited cell proliferation and induced cell apoptosis in vitro and significantly improved the response of HER2-positive breast cancer cells to trastuzumab in vivo compared with the controls. Here, ERBB2 is linked to breast carcinoma.